Nanowear received FDA Breakthrough Device Designation in February 2026 for its SimpleSense-Wrist patch, a wearable sensor designed to monitor vascular health non-invasively, a designation that grants the company expedited FDA review and more frequent agency interaction as it pursues full regulatory clearance, support the company said will meaningfully shorten its path toward a marketable product. The device adds to Nanowear’s existing SimpleSense product line, which has focused on remote cardiac and pulmonary monitoring using fabric-based sensors embedded in wearable garments rather than traditional rigid electronic devices.
What Breakthrough Device Designation Actually Means
The FDA’s Breakthrough Device program is reserved for technologies that could provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions, granting manufacturers priority review, more frequent and substantive interaction with FDA staff during development, and in some cases faster paths to Medicare coverage decisions after clearance. The designation does not guarantee eventual approval or clearance, but it signals that the FDA views the underlying technology as addressing a significant unmet clinical need, a distinction that can meaningfully influence investor and clinical partner interest even before a product reaches market, interest Nanowear will need to sustain through what is likely to be a multi-year clinical validation process.
How Nanowear’s Fabric-Sensor Approach Differs From Conventional Wearables
Unlike most consumer and clinical wearables, which rely on rigid sensor modules worn on the wrist or chest, Nanowear has built its technology around textile-based sensors that can be woven into clothing or worn as flexible patches, an approach the company argues allows for more comfortable, continuous long-term monitoring than rigid devices that patients may be less likely to wear consistently, particularly among older patients or those managing multiple chronic conditions simultaneously. The SimpleSense-Wrist extends this fabric-sensor approach specifically to vascular monitoring, aiming to detect changes in blood vessel function that can serve as early indicators of cardiovascular risk.
Why Vascular Monitoring Is a Harder Problem Than Heart Rate Tracking
Most consumer wearables on the market today measure heart rate and rhythm relatively well using photoplethysmography or electrocardiogram sensors, technology that has matured considerably over the past decade, but non-invasive, continuous vascular function monitoring, assessing how well blood vessels are dilating and responding to physiological changes, has proven considerably more technically challenging and has not achieved the same level of consumer wearable maturity. Nanowear’s pursuit of FDA Breakthrough status specifically for vascular monitoring reflects an attempt to address a genuine gap in non-invasive cardiovascular monitoring technology rather than incrementally improving an already well-served measurement category that larger competitors have already saturated.
The Clinical Case for Earlier Vascular Risk Detection
Vascular dysfunction often precedes more serious cardiovascular events including heart attack and stroke, and cardiologists have long sought better tools for detecting early vascular changes outside of clinical settings, where testing has traditionally required specialized equipment and in-person visits that many patients, particularly those without regular cardiology follow-up, simply never receive. A validated, continuous, non-invasive vascular monitoring wearable could, if proven effective, allow earlier intervention for patients showing concerning trends, potentially before they experience symptoms significant enough to prompt a clinical visit.
The Skepticism Facing Nanowear’s Technology
Medical device analysts have noted that Breakthrough Device Designation, while a meaningful regulatory signal, represents an early stage in a product’s development and clearance pathway, and that Nanowear will still need to generate robust clinical validation data demonstrating the SimpleSense-Wrist’s accuracy against established vascular function measurement methods before full FDA clearance. Some cardiologists have also cautioned that novel wearable sensing modalities often take longer than initially expected to achieve the accuracy and reliability needed for clinical decision-making, a pattern seen with several earlier wearable health technologies that initially showed promise in small studies before encountering accuracy challenges at larger scale.
What’s Next
Nanowear is expected to continue clinical validation studies for the SimpleSense-Wrist as it works toward full FDA clearance, a process that could take one to several years depending on study results and regulatory feedback through the Breakthrough Device program’s expedited interaction process. If successful, the device would expand Nanowear’s existing cardiac and pulmonary monitoring product line into a new vascular monitoring category that could appeal to both clinical cardiology practices and, eventually, a broader consumer cardiovascular wellness market that has shown growing appetite for continuous, non-invasive health tracking beyond the wrist-based heart rate sensors already widely available.
Photo: Nutrisense Inc / PEXELS via Pexels
